- Home
- KIDS vs AUTL Comparison
KIDS vs AUTL Comparison
Compare KIDS & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIDS | AUTL |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.3M | 433.8M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KIDS | AUTL |
|---|---|---|
| Price | $17.58 | $1.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $24.75 | $8.67 |
| AVG Volume (30 Days) | 160.7K | ★ 2.7M |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $227,410,000.00 | $51,128,000.00 |
| Revenue This Year | $16.58 | $669.49 |
| Revenue Next Year | $12.42 | $91.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 19.90 | ★ 406.67 |
| 52 Week Low | $15.28 | $1.11 |
| 52 Week High | $27.60 | $2.80 |
Technical Indicators
Market Signals| Indicator | KIDS | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 65.42 |
| Support Level | $17.07 | $1.63 |
| Resistance Level | $18.04 | $2.05 |
| Average True Range (ATR) | 0.66 | 0.11 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 38.89 | 68.31 |
Price Performance
Historical ComparisonAbout KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.